Here are the top 5 biosimilar articles for the week of December 14, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of December 14, 2020.
Number 5: Studies of trastuzumab biosimilars in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer have yielded significant findings, according to presentations at the 2020 San Antonio Breast Cancer Symposium.
Number 4: Investigators studying biosimilar savings and use rates in HER2-positive breast cancer observed dramatically increased usage of trastuzumab biosimilars and said payer policy appears to have contributed to higher biosimilar utilization.
Number 3: Celltrion’s high-concentration, citrate-free adalimumab biosimilar candidate (CT-P17, Yuflyma) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Number 2: Sarfaraz K. Niazi, PhD, an advisory board member for The Center for Biosimilars, published an opinion piece on Boehringer Ingelheim’s recent filing of a citizen’s petition asking the FDA to change its interpretation of the term strength in the Public Health Service Act.
Number 1: Biocon Biologics and Mylan have received a positive recommendation from the EMA CHMP for the marketing approval of their biosimilar insulin aspart candidate (Kixelle) for the treatment of type 1 and type 2 diabetes.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.